COVID-19 vaccine supply chain delays almost inevitable, expert says

23 September 2020

The overwhelming focus of media reports on COVID-19 vaccine candidates is on whether they will provide positive Phase III data and meet the approval of regulators, and also whether they can be manufactured in sufficient quantity to cope with demand.

However, the unprecedented scale of its impeding distribution means a hugely complex supply chains need to be created immediately if there is any chance of it being delivered swiftly, according to Madhav Durbha, group vice president of industry strategy, LLamasoft, a global AI and logistics solutions provider.

'Supply chain must work optimally'

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK